Janus kinase-3 dependent inflammatory responses in allergic asthma

International Immunopharmacology

Volumn 10, Issue 8, 2010, Pages 829-836

  Malaviya, Rama ^a   Laskin, Debra L ^a   Malaviya, Ravi ^b  

^a RUTGERS UNIVERSITY   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Allergy; Asthma; Janus kinase; Lung inflammation

Indexed keywords

CHEMOKINE; CHYMASE; HISTAMINE; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; JANUS KINASE 3; LEUKOTRIENE; PROSTAGLANDIN; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ASTHMA; BRONCHUS MUCOSA; CELLULAR IMMUNITY; DENDRITIC CELL; EPITHELIUM CELL; HUMAN; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY CELL; MACROPHAGE; MAST CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ASTHMA; DENDRITIC CELLS; DRUG DESIGN; HUMANS; IMMUNOGLOBULIN E; JANUS KINASE 3; LUNG; MACROPHAGES, ALVEOLAR; MAST CELLS; PNEUMONIA; RESPIRATORY MUCOSA; SIGNAL TRANSDUCTION;

EID: 77954959277     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.04.014     Document Type: Review

References (137)

1. Chen H., Johnson C.A., Haselkorn T., Lee J.H., Israel E. Subspecialty differences in asthma characteristics and management. Mayo Clin Proc 2008, 83:786-793.
2. Holgate S.T. Airway inflammation and remodeling in asthma: current concepts. Mol Biotechnol 2002, 22:179-189.
3. Davies D.E., Wicks J., Powell R.M., Puddicombe S.M., Holgate S.T. Airway remodeling in asthma: new insights. J Allergy Clin Immunol 2003, 111:215-225.
4. Holgate S.T. Asthma: more than an inflammatory disease. Curr Opin Allergy Clin Immunol 2002, 2:27-29.
5. Holgate S.T. Pathogenesis of asthma. Clin Exp Allergy 2008, 38:872-897.
6. Phipps S., Benyahia F., Ou T.T., Barkans J., Robinson D.S., Kay A.B. Acute allergen-induced airway remodeling in atopic asthma. Am J Respir Cell Mol Biol 2004, 31:626-632.
7. Bharadwaj A.S., Bewtra A.K., Agrawal D.K. Dendritic cells in allergic airway inflammation. Can J Physiol Pharmacol 2007, 85:686-699.
8. Barnes P.J., Chung K.F., Page C.P. Inflammatory mediators of asthma: an update. Pharmacol Rev 1998, 50:515-596.
9. Puxeddu I., Levi-Schaffer F. Mast cells and eosinophils: the hallmark of asthma. Paediatr Respir Rev 2004, 5 Suppl A:S31-S34.
10. Ichinose M., Barnes P.J. Cytokine-directed therapy in asthma. Curr Drug Targets Inflamm Allergy 2004, 3:263-269.
11. O'Byrne P.M. The demise of anti IL-5 for asthma, or not. Am J Respir Crit Care Med 2007, 176:1059-1060.
12. Kon O.M., Sihra B.S., Loh L.C., Barkans J., Compton C.H., Barnes N.C., et al. The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma. Eur Respir J 2001, 18:45-52.
13. Ong Y.E., Menzies-Gow A., Barkans J., Benyahia F., Ou T.T., Ying S., et al. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol 2005, 116:558-564.
14. Felix Toledo R., Negro Alvarez J.M. Anti-IgE (omalizumab): a hope in the treatment of allergic diseases. Rev Clin Esp 2003, 203:196-198.
15. Tantisira K.G., Drazen J.M. Genetics and pharmacogenetics of the leukotriene pathway. J Allergy Clin Immunol 2009, 124:422-427.
16. Kudlacz E., Conklyn M., Andresen C., Whitney-Pickett C., Changelian P. The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur J Pharmacol 2008, 582:154-161.
17. Malaviya R., Chen C.L., Navara C., Liu X.P., Keenan M., Waurzyniak B., et al. Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6, 7-dimethoxyquinazoline (WHI-P97). J Pharmacol Exp Ther 2000, 295:912-926.
18. Verbsky J.W., Randolph D.A., Shornick L.P., Chaplin D.D. Nonhematopoietic expression of Janus kinase 3 is required for efficient recruitment of Th2 lymphocytes and eosinophils in OVA-induced airway inflammation. J Immunol 2002, 168:2475-2482.
19. Ghoreschi K., Laurence A., O'Shea J.J. Janus kinases in immune cell signaling. Immunol Rev 2009, 228:273-287.
20. Thomis D.C., Berg L.J. The role of Jak3 in lymphoid development, activation, and signaling. Curr Opin Immunol 1997, 9:541-547.
21. Thomis D.C., Gurniak C.B., Tivol E., Sharpe A.H., Berg L.J. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 1995, 270:794-797.
22. Uchiyama T., Kumaki S., Fujiwara M., Nishida Y., Hakozaki I., Imai K., et al. A novel JAK3 mutation in a Japanese patient with severe combined immunodeficiency. Pediatr Int 2005, 47:575-578.
23. Buckley R.H., Schiff R.I., Schiff S.E., Markert M.L., Williams L.W., Harville T.O., et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 1997, 130:378-387.
24. Imada K., Leonard W.J. The Jak-STAT pathway. Mol Immunol 2000, 37:1-11.
25. Tibbles H.E., Vassilev A., Wendorf H., Schonhoff D., Zhu D., Lorenz D., et al. Role of a JAK3-dependent biochemical signaling pathway in platelet activation and aggregation. J Biol Chem 2001, 276:17815-17822.
26. Sareila O., Korhonen R., Karpanniemi O., Nieminen R., Kankaanranta H., Moilanen E. Janus kinase 3 inhibitor WHI-P154 in macrophages activated by bacterial endotoxin: differential effects on the expression of iNOS, COX-2 and TNF-alpha. Int Immunopharmacol 2008, 8:100-108.
27. Malaviya R., Uckun F.M. Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions. Biochem Biophys Res Commun 1999, 257:807-813.
28. Malaviya R., Zhu D., Dibirdik I., Uckun F.M. Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. J Biol Chem 1999, 274:27028-27038.
29. Wilson L.J., Malaviya R., Yang C., Argentieri R., Wang B., Chen X., et al. Synthetic staurosporines via a ring closing metathesis strategy as potent JAK3 inhibitors and modulators of allergic responses. Bioorg Med Chem Lett 2009, 19:3333-3338.
30. Suzuki K., Nakajima H., Watanabe N., Kagami S., Suto A., Saito Y., et al. Role of common cytokine receptor gamma chain (gamma(c))- and Jak3-dependent signaling in the proliferation and survival of murine mast cells. Blood 2000, 96:2172-2180.
31. Marone G., Triggiani M., de Paulis A. Mast cells and basophils: friends as well as foes in bronchial asthma?. Trends Immunol 2005, 26:25-31.
32. Boyce J.A. The role of mast cells in asthma. Prostaglandins Leukot Essent Fatty Acids 2003, 69:195-205.
33. Sur R., Cavender D., Malaviya R. Different approaches to study mast cell functions. Int Immunopharmacol 2007, 7:555-567.
34. Hart P.H. Regulation of the inflammatory response in asthma by mast cell products. Immunol Cell Biol 2001, 79:149-153.
35. Galli S.J. Mast cells and basophils. Curr Opin Hematol 2000, 7:32-39.
36. Ramos B.F., Zhang Y., Qureshi R., Jakschik B.A. Mast cells are critical for the production of leukotrienes responsible for neutrophil recruitment in immune complex-induced peritonitis in mice. J Immunol 1991, 147:1636-1641.
37. Galli S.J., Gordon J.R., Wershil B.K. Cytokine production by mast cells and basophils. Curr Opin Immunol 1991, 3:865-872.
38. Galli S.J. Complexity and redundancy in the pathogenesis of asthma: reassessing the roles of mast cells and T cells. J Exp Med 1997, 186:343-347.
39. Holgate S. Mediator and cytokine mechanisms in asthma. Thorax 1993, 48:103-109.
40. Malaviya R., Abraham S.N. Role of mast cell leukotrienes in neutrophil recruitment and bacterial clearance in infectious peritonitis. J Leukoc Biol 2000, 67:841-846.
41. Malaviya R., Ikeda T., Ross E., Abraham S.N. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 1996, 381:77-80.
42. Luster A.D., Tager A.M. T-cell trafficking in asthma: lipid mediators grease the way. Nat Rev Immunol 2004, 4:711-724.
43. O'Sullivan S. On the role of PGD2 metabolites as markers of mast cell activation in asthma. Acta Physiol Scand Suppl 1999, 644:1-74.
44. Rajakulasingam K., Gnanakumaran G., Church M.K., Howarth P.H., Holgate S.T. Interactive effect of inhaled bradykinin with histamine and PGD2 in bronchial asthma. J Appl Physiol 1993, 75:1996-2002.
45. Doggrell S.A. Cytokines, signaling and diseases - a pharmacologist's view. Drug News Perspect 2004, 17:67-80.
46. He S., Aslam A., Gaca M.D., He Y., Buckley M.G., Hollenberg M.D., et al. Inhibitors of tryptase as mast cell-stabilizing agents in the human airways: effects of tryptase and other agonists of proteinase-activated receptor 2 on histamine release. J Pharmacol Exp Ther 2004, 309:119-126.
47. He S., Zheng J. Induction of inflammatory cell accumulation using human mast cell tryptases. Asian Pac J Allergy Immunol 2003, 21:145-151.
48. Hallgren J., Pejler G. Biology of mast cell tryptase. An inflammatory mediator. FEBS J 2006, 273:1871-1895.
49. Barnes P.J., Lim S. Inhibitory cytokines in asthma. Mol Med Today 1998, 4:452-458.
50. Bissonnette E.Y., Befus A.D. Mast cells in asthma. Can Respir J 1998, 5:23-24.
51. Rivera J., Fierro N.A., Olivera A., Suzuki R. New insights on mast cell activation via the high affinity receptor for IgE. Adv Immunol 2008, 98:85-120.
52. Yamasaki S., Saito T. Progress in allergy signal research on mast cells: signal regulation of multiple mast cell responses through FcepsilonRI. J Pharmacol Sci 2008, 106:336-340.
53. Rivera J., Gilfillan A.M. Molecular regulation of mast cell activation. J Allergy Clin Immunol 2006, 117:1214-1225. quiz 26.
54. Gomez G., Schwartz L., Kepley C. Syk deficiency in human non-releaser lung mast cells. Clin Immunol 2007, 125:112-115.
55. Malaviya R., Navara C., Uckun F.M. Role of Janus kinase 3 in mast cell-mediated innate immunity against gram-negative bacteria. Immunity 2001, 15:313-321.
56. Malaviya R., Uckun F.M. Role of STAT6 in IgE receptor/FcepsilonRI-mediated late phase allergic responses of mast cells. J Immunol 2002, 168:421-426.
57. Okayama Y., Kawakami T. Development, migration, and survival of mast cells. Immunol Res 2006, 34:97-115.
58. Suzuki K., Nakajima H., Saito Y., Saito T., Leonard W.J., Iwamoto I. Janus kinase 3 (Jak3) is essential for common cytokine receptor gamma chain (gamma(c))-dependent signaling: comparative analysis of gamma(c), Jak3, and gamma(c) and Jak3 double-deficient mice. Int Immunol 2000, 12:123-132.
59. Malaviya R., Abraham S.N. Interaction of bacteria with mast cells. Meth Enzymol 1995, 253:27-43.
60. Matsuzawa S., Sakashita K., Kinoshita T., Ito S., Yamashita T., Koike K. IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. J Immunol 2003, 170:3461-3467.
61. Hu Z.Q., Zhao W.H., Shimamura T. Regulation of mast cell development by inflammatory factors. Curr Med Chem 2007, 14:3044-3050.
62. Irani A.M., Craig S.S., DeBlois G., Elson C.O., Schechter N.M., Schwartz L.B. Deficiency of the tryptase-positive, chymase-negative mast cell type in gastrointestinal mucosa of patients with defective T lymphocyte function. J Immunol 1987, 138:4381-4386.
63. Masuda E.S., Schmitz J. Syk inhibitors as treatment for allergic rhinitis. Pulm Pharmacol Ther 2008, 21:461-467.
64. Malaviya R., Malaviya R., Jakschik B.A. Reversible translocation of 5-lipoxygenase in mast cells upon IgE/antigen stimulation. J Biol Chem 1993, 268:4939-4944.
65. Salvi S.S., Krishna M.T., Sampson A.P., Holgate S.T. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest 2001, 119:1533-1546.
66. Malaviya R., Chen C.L., Liu X.P., Uckun F.M. In vivo pharmacokinetics and anti-anaphylactic activity of the novel mast cell inhibitor 4-(4'-hydroxylphenyl)-amino-6, 7-dimethoxyquinazoline (WHI-P131). Am J Ther 2001, 8:35-39.
67. Ishizaka K., Ishizaka T. Physicochemical properties of reaginic antibody. 1. Association of reaginic activity with an immunoglobulin other than gammaA- or gammaG-globulin. J Allergy 1966, 37:169-185.
68. Kagamimori S., Naruse Y., Watanabe M., Nohara S., Okada A. An epidemiological study on total and specific IgE levels in Japanese schoolchildren. Clin Allergy 1982, 12:561-568.
69. Oryszczyn M.P., Annesi-Maesano I., Charpin D., Paty E., Maccario J., Kauffmann F. Relationships of active and passive smoking to total IgE in adults of the Epidemiological Study of the Genetics and Environment of Asthma, Bronchial Hyperresponsiveness, and Atopy (EGEA). Am J Respir Crit Care Med 2000, 161:1241-1246.
70. Simoni M., Biavati P., Baldacci S., Carrozzi L., Pedreschi M., Di Pede F., et al. The Po River Delta epidemiological survey: reference values of total serum IgE levels in a normal population sample of North Italy (8-78yrs). Eur J Epidemiol 2001, 17:231-239.
71. Siroux V., Curt F., Oryszczyn M.P., Maccario J., Kauffmann F. Role of gender and hormone-related events on IgE, atopy, and eosinophils in the Epidemiological Study on the Genetics and Environment of Asthma, bronchial hyperresponsiveness and atopy. J Allergy Clin Immunol 2004, 114:491-498.
72. Ames S.A., Gleeson C.D., Kirkpatrick P. Omalizumab. Nat Rev Drug Discov 2004, 3:199-200.
73. D'Amato G., Salzillo A., Piccolo A., D'Amato M., Liccardi G. A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma. Ther Clin Risk Manag 2007, 3:613-619.
74. Holgate S.T., Djukanovic R., Casale T., Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005, 35:408-416.
75. Chang T.W., Shiung Y.Y. Anti-IgE as a mast cell-stabilizing therapeutic agent. J Allergy Clin Immunol 2006, 117:1203-1212. quiz 13.
76. Kopf M., Le Gros G., Bachmann M., Lamers M.C., Bluethmann H., Kohler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993, 362:245-248.
77. Saemann M.D., Kelemen P., Zeyda M., Bohmig G., Staffler G., Zlabinger G.J. CD40 triggered human monocyte-derived dendritic cells convert to tolerogenic dendritic cells when JAK3 activity is inhibited. Transplant Proc 2002, 34:1407-1408.
78. Saemann M.D., Zeyda M., Stulnig T.M., Bohmig G.A., Wekerle T., Horl W.H., et al. Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation. Transpl Int 2004, 17:481-489.
79. Snapper C.M., Paul W.E. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987, 236:944-947.
80. Xu L., Rothman P. IFN-gamma represses epsilon germline transcription and subsequently down-regulates switch recombination to epsilon. Int Immunol 1994, 6:515-521.
81. Corry D.B., Kheradmand F. Biology and therapeutic potential of the interleukin-4/interleukin-13 signaling pathway in asthma. Am J Respir Med 2002, 1:185-193.
82. Gessner A., Rollinghoff M. Biologic functions and signaling of the interleukin-4 receptor complexes. Immunobiology 2000, 201:285-307.
83. Kuperman D.A., Schleimer R.P. Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma. Curr Mol Med 2008, 8:384-392.
84. Chatila T.A. Interleukin-4 receptor signaling pathways in asthma pathogenesis. Trends Mol Med 2004, 10:493-499.
85. Nelms K., Keegan A.D., Zamorano J., Ryan J.J., Paul W.E. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999, 17:701-738.
86. Pernis A.B., Rothman P.B. JAK-STAT signaling in asthma. J Clin Invest 2002, 109:1279-1283.
87. Ihle J.N., Kerr I.M. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet 1995, 11:69-74.
88. Igarashi H., Kuwahara K., Yoshida M., Xing Y., Maeda K., Nakajima K., et al. GANP suppresses the arginine methyltransferase PRMT5 regulating IL-4-mediated STAT6-signaling to IgE production in B cells. Mol Immunol 2009, 46:1031-1041.
89. Kim J.H., Park H.H., Lee C.E. IGF-1 potentiation of IL-4-induced CD23/Fc(epsilon)RII expression in human B cells. Mol Cells 2003, 15:307-312.
90. Ryan J.J., DeSimone S., Klisch G., Shelburne C., McReynolds L.J., Han K., et al. IL-4 inhibits mouse mast cell Fc epsilonRI expression through a STAT6-dependent mechanism. J Immunol 1998, 161:6915-6923.
91. Schedel M., Carr D., Klopp N., Woitsch B., Illig T., Stachel D., et al. A signal transducer and activator of transcription 6 haplotype influences the regulation of serum IgE levels. J Allergy Clin Immunol 2004, 114:1100-1105.
92. Gernez Y., Tirouvanziam R., Nguyen K.D., Herzenberg L.A., Krensky A.M., Nadeau K.C. Altered phosphorylated signal transducer and activator of transcription profile of CD4+CD161+ T cells in asthma: modulation by allergic status and oral corticosteroids. J Allergy Clin Immunol 2007, 120:1441-1448.
93. Junttila I.S., Mizukami K., Dickensheets H., Meier-Schellersheim M., Yamane H., Donnelly R.P., et al. Tuning sensitivity to IL-4 and IL-13: differential expression of IL-4Ralpha, IL-13Ralpha1, and gammac regulates relative cytokine sensitivity. J Exp Med 2008, 205:2595-2608.
94. Cortes J.R., Perez G.M., Rivas M.D., Zamorano J. Kaempferol inhibits IL-4-induced STAT6 activation by specifically targeting JAK3. J Immunol 2007, 179:3881-3887.
95. Matsumoto M., Ra C., Kawamoto K., Sato H., Itakura A., Sawada J., et al. IgE hyperproduction through enhanced tyrosine phosphorylation of Janus kinase 3 in NC/Nga mice, a model for human atopic dermatitis. J Immunol 1999, 162:1056-1063.
96. Jabara H.H., Buckley R.H., Roberts J.L., Lefranc G., Loiselet J., Khalil G., et al. Role of JAK3 in CD40-mediated signaling. Blood 1998, 92:2435-2440.
97. van Kooten C., Banchereau J. Immune regulation by CD40-CD40-L interactions. Front Biosci 1997, 2:d1-d11.
98. Cagnoni F., Oddera S., Giron-Michel J., Riccio A.M., Olsson S., Dellacasa P., et al. CD40 on adult human airway epithelial cells: expression and proinflammatory effects. J Immunol 2004, 172:3205-3214.
99. Brady K., Fitzgerald S., Ingvarsson S., Borrebaeck C.A., Moynagh P.N. CD40 employs p38 MAP kinase in IgE isotype switching. Biochem Biophys Res Commun 2001, 289:276-281.
100. Wagner D.H., Stout R.D., Suttles J. Role of the CD40-CD40 ligand interaction in CD4+ T cell contact-dependent activation of monocyte interleukin-1 synthesis. Eur J Immunol 1994, 24:3148-3154.
101. Revy P., Hivroz C., Andreu G., Graber P., Martinache C., Fischer A., et al. Activation of the Janus kinase 3-STAT5a pathway after CD40 triggering of human monocytes but not of resting B cells. J Immunol 1999, 163:787-793.
102. Shen C.H., Stavnezer J. Activation of the mouse Ig germline epsilon promoter by IL-4 is dependent on AP-1 transcription factors. J Immunol 2001, 166:411-423.
103. Fuleihan R., Ahern D., Geha R.S. Expression of the CD40 ligand in T lymphocytes and induction of IgE isotype switching. Int Arch Allergy Immunol 1995, 107:43-44.
104. Kawabe T., Naka T., Yoshida K., Tanaka T., Fujiwara H., Suematsu S., et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1994, 1:167-178.
105. Xu J., Foy T.M., Laman J.D., Elliott E.A., Dunn J.J., Waldschmidt T.J., et al. Mice deficient for the CD40 ligand. Immunity 1994, 1:423-431.
106. Yamada T., Zhu D., Saxon A., Zhang K. CD45 controls interleukin-4-mediated IgE class switch recombination in human B cells through its function as a Janus kinase phosphatase. J Biol Chem 2002, 277:28830-28835.
107. van Kooten C., Fiore N., Trouw L.A., Csomor E., Xu W., Castellano G., et al. Complement production and regulation by dendritic cells: molecular switches between tolerance and immunity. Mol Immunol 2008, 45:4064-4072.
108. Lambrecht B.N. Lung dendritic cells: targets for therapy in allergic disease. Curr Mol Med 2008, 8:393-400.
109. Lukens M.V., Kruijsen D., Coenjaerts F.E., Kimpen J.L., van Bleek G.M. Respiratory syncytial virus-induced activation and migration of respiratory dendritic cells and subsequent antigen presentation in the lung-draining lymph node. J Virol 2009, 83:7235-7243.
110. Tsoumakidou M., Demedts I.K., Brusselle G.G., Jeffery P.K. Dendritic cells in chronic obstructive pulmonary disease: new players in an old game. Am J Respir Crit Care Med 2008, 177:1180-1186.
111. von Garnier C., Filgueira L., Wikstrom M., Smith M., Thomas J.A., Strickland D.H., et al. Anatomical location determines the distribution and function of dendritic cells and other APCs in the respiratory tract. J Immunol 2005, 175:1609-1618.
112. Bellini A., Vittori E., Marini M., Ackerman V., Mattoli S. Intraepithelial dendritic cells and selective activation of Th2-like lymphocytes in patients with atopic asthma. Chest 1993, 103:997-1005.
113. Matsuda H., Suda T., Hashizume H., Yokomura K., Asada K., Suzuki K., et al. Alteration of balance between myeloid dendritic cells and plasmacytoid dendritic cells in peripheral blood of patients with asthma. Am J Respir Crit Care Med 2002, 166:1050-1054.
114. van Rijt L.S., Lambrecht B.N. Role of dendritic cells and Th2 lymphocytes in asthma: lessons from eosinophilic airway inflammation in the mouse. Microsc Res Tech 2001, 53:256-272.
115. van Rijt L.S., Prins J.B., Leenen P.J., Thielemans K., de Vries V.C., Hoogsteden H.C., et al. Allergen-induced accumulation of airway dendritic cells is supported by an increase in CD31(hi)Ly-6C(neg) bone marrow precursors in a mouse model of asthma. Blood 2002, 100:3663-3671.
116. van Kooten C., Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000, 67:2-17.
117. Quezada S.A., Jarvinen L.Z., Lind E.F., Noelle R.J. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004, 22:307-328.
118. Saemann M.D., Diakos C., Kelemen P., Kriehuber E., Zeyda M., Bohmig G.A., et al. Prevention of CD40-triggered dendritic cell maturation and induction of T-cell hyporeactivity by targeting of Janus kinase 3. Am J Transplant 2003, 3:1341-1349.
119. Skokos D., Botros H.G., Demeure C., Morin J., Peronet R., Birkenmeier G., et al. Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. J Immunol 2003, 170:3037-3045.
120. McLachlan J.B., Shelburne C.P., Hart J.P., Pizzo S.V., Goyal R., Brooking-Dixon R., et al. Mast cell activators: a new class of highly effective vaccine adjuvants. Nat Med 2008, 14:536-541.
121. Malaviya R., Georges A. Regulation of mast cell-mediated innate immunity during early response to bacterial infection. Clin Rev Allergy Immunol 2002, 22:189-204.
122. Bentley A.M., Menz G., Storz C., Robinson D.S., Bradley B., Jeffery P.K., et al. Identification of T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in intrinsic asthma. Relationship to symptoms and bronchial responsiveness. Am Rev Respir Dis 1992, 146:500-506.
123. Gosset P., Tillie-Leblond I., Oudin S., Parmentier O., Wallaert B., Joseph M., et al. Production of chemokines and proinflammatory and antiinflammatory cytokines by human alveolar macrophages activated by IgE receptors. J Allergy Clin Immunol 1999, 103:289-297.
124. Laskin D.L. Macrophages and inflammatory mediators in chemical toxicity: a battle of forces. Chem Res Toxicol 2009, 22:1376-1385.
125. Eynott P.R., Groneberg D.A., Caramori G., Adcock I.M., Donnelly L.E., Kharitonov S., et al. Role of nitric oxide in allergic inflammation and bronchial hyperresponsiveness. Eur J Pharmacol 2002, 452:123-133.
126. Mangan J.K., Rane S.G., Kang A.D., Amanullah A., Wong B.C., Reddy E.P. Mechanisms associated with IL-6-induced up-regulation of Jak3 and its role in monocytic differentiation. Blood 2004, 103:4093-4101.
127. Sareila O., Korhonen R., Karpanniemi O., Nieminen R., Kankaanranta H., Moilanen E. JAK inhibitors AG-490 and WHI-P154 decrease IFN-gamma-induced iNOS expression and NO production in macrophages. Mediators Inflamm 2006, 2006:1-7.
128. Boxall C., Holgate S.T., Davies D.E. The contribution of transforming growth factor-beta and epidermal growth factor signalling to airway remodelling in chronic asthma. Eur Respir J 2006, 27:208-229.
129. Howell J.E., McAnulty R.J. TGF-beta: its role in asthma and therapeutic potential. Curr Drug Targets 2006, 7:547-565.
130. Wang G., Qian P., Jackson F.R., Qian G., Wu G. Sequential activation of JAKs, STATs and xanthine dehydrogenase/oxidase by hypoxia in lung microvascular endothelial cells. Int J Biochem Cell Biol 2008, 40:461-470.
131. Ying S., O'Connor B., Ratoff J., Meng Q., Mallett K., Cousins D., et al. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol 2005, 174:8183-8190.
132. Liu Y.J. Thymic stromal lymphopoietin: master switch for allergic inflammation. J Exp Med 2006, 203:269-273.
133. Leir S.H., Holgate S.T., Lackie P.M. Inflammatory cytokines can enhance CD44-mediated airway epithelial cell adhesion independently of CD44 expression. Am J Physiol Lung Cell Mol Physiol 2003, 285:L1305-L1311.
134. Liu J., Kern J.A. Neuregulin-1 activates the JAK-STAT pathway and regulates lung epithelial cell proliferation. Am J Respir Cell Mol Biol 2002, 27:306-313.
135. Doucet C., Jasmin C., Azzarone B. Unusual interleukin-4 and -13 signaling in human normal and tumor lung fibroblasts. Oncogene 2000, 19:5898-5905.
136. Verbsky J.W., Bach E.A., Fang Y.F., Yang L., Randolph D.A., Fields L.E. Expression of Janus kinase 3 in human endothelial and other non-lymphoid and non-myeloid cells. J Biol Chem 1996, 271:13976-13980.
137. Ghoreschi K., Laurence A., O'Shea J.J. Selectivity and therapeutic inhibition of kinases: to be or not to be?. Nat Immunol 2009, 10:356-360.